Existing investors Pfizer Ventures and Merck GHI helped the precision cancer test developer take its total funding past the $130m mark.
US-based precision cancer therapy developer Strata Oncology has closed a $90m series C round led by investment manager Wellington Management that included pharmaceutical firms Pfizer and Merck & Co.
Cormorant Asset Management, Monashee Investment Management, Highside Capital Management, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund also contributed to the round.
Pfizer and Merck participated through respective corporate venturing units Pfizer Ventures and Merck Global Health Innovation Fund (Merck GHI), and JP Morgan was sole placement agent…
